However, HbA1c levels were comparable between the groups(DPP-4 inhibitor group: 7.3±1.2% vs. Control: 7.4±1.1%, p=0.28), with nosignificant difference, suggesting that glycemic control at baseline was similarand minimizing the impact of diabetes severity on our findings. The gene discussed is DPP4; the disease is diabetes mellitus.